Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDDDD.L Share News (DDDD)

  • There is currently no data for DDDD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: RWS and James Cropper sink on profit warnings

Wed, 23rd Mar 2022 11:21

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

----------

AIM - WINNERS

----------

4D Pharma PLC, up 37% at 61.45 pence, 12-month range 24.46p-135.00p. The pharmaceutical company says its therapeutic treatment MRx0518, in combination Merck's Keytruda, met its primary efficacy endpoint ahead of trial enrolment completion.

----------

AIM - LOSERS

----------

RWS Holdings PLC, down 27% at 342.00p, 12-month range 326.00p-701.00p. The technology-enabled language services provider warns its annual performance is set to be at the lower end of expectations.

RWS will no longer provide services or technology to Russian-owned businesses, and also expects reduced demand for translation into Russian from non-Russian owned companies. As a result, revenue growth from the Language Services unit is set to moderate, and RWS's overall performance for the year is anticipated to be at the lower end of market expectations.

----------

James Cropper PLC, down 18% at 1,002.00p, 12-month range 1,002.00p-1,650.00p. Shares in the paper products manufacturer hit a 12-month low as it warns it will miss previous expectations for profit. For the year ending March 26, James Cropper notes 30% growth in sales, ahead of prior market expectations due to strong demand across all divisions. However, it now expects adjusted pretax profit of GBP3.5 million, a sharp rise from GBP1.1 million the year before, but below prior expectations of GBP4.9 million. This is due to the conflict between Russia and Ukraine, and the resulting jump in energy costs, which affected the Paper division the most, due to being the most energy-intensive division.

----------

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
2 Feb 2015 16:06

UK AGM, EGM Calendar - Week Ahead

Read more
21 Jan 2015 08:51

4D Pharma Raises GBP34.8 Million Through Share Placing (ALLISS)

Read more
23 Sep 2014 12:24

4d Pharma Posts First-Half Loss, Says Pipeline Is Strong

Read more
2 Sep 2014 10:21

4D pharma progresses with IBS and Crohn's treatments

4D pharma has announced that its treatments for Irritable Bowel Syndrome (IBS) and Paediatric Crohn's Disease (PCD) are expected to enter clinical studies in the second quarter of 2015. The studies, which will be focused on evaluating safety and tolerability of the products as well as some clinica

Read more
2 Sep 2014 07:26

UK MORNING BRIEFING: Weir Group Leads Firm London Market On Upgrade

Read more
2 Sep 2014 06:55

4d Pharma's Blautix, Thetanix To Start Clinical Studies In 2015

Read more
7 Aug 2014 08:28

4d Pharma Gets Orphan Drug Designation From US FDA

Read more
7 Aug 2014 07:32

UK MORNING BRIEFING: Old Mutual, Coca-Cola HBC And RSA Weigh On FTSE

Read more
18 Jul 2014 10:00

4d Pharma Buys Microbiota For GBP2.0 Million

Read more
18 Jul 2014 07:25

UK MORNING BRIEFING: Shares Lower On Ukraine Crash, Gaza Offensive

Read more
25 Jun 2014 10:11

4d Pharma Raises GBP21.5 Million In Share Placing

Read more
25 Jun 2014 07:40

UK MORNING BRIEFING: Shares Down; Land Securities Buys Into Bluewater

Read more
4 Jun 2014 10:17

4d Pharma Raises Stake In GT Biologics To 83.5%

LONDON (Alliance News) - 4d Pharma PLC Wednesday said it has acquired a further 37.5% stake in GT Biologics Ltd for GBP1.22 million in new 4d Pharma shares, taking its total shareholding in the GT Biologics to 83.5%. 4d Pharma, which focuses on significant new therapeutic areas, said the ac

Read more
4 Jun 2014 07:53

4d pharma increases stake in GT Biologics to nearly 84%

4d pharma, an AIM-listed pharmaceutical company focused on new therapeutic areas, has added an additional 37.5% to its stake in GT Biologics taking its current holding to around 83.5%. The £1.22m consideration was satisfied by the issue of 699,500 new 4d shares at 175p each, reflecting their avera

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.